Today’s edition of BioStock Live features the Swedish medtech company Acarix. CEO Per Persson tells us more about the company and its product, the CADScor System – a diagnostic device for healthcare professionals investigating patients who suffer from symptoms related to coronary artery disease. Acarix has recently received market approval for CADScor in the US, and the CEO expects a news-intensive 2021.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.